西尼莫德减少实验性卒中中年小鼠脑浸润但不减少病灶体积
该研究在中年野生型小鼠短暂大脑中动脉闭塞模型中,给予西尼莫德(3 mg/kg 腹腔注射)或溶媒治疗6天,用磁共振成像和行为学评估卒中结局,并用流式细胞术分析免疫细胞。结果显示西尼莫德显著诱导第7天淋巴细胞减少并减少中枢神经系统T淋巴细胞积聚,但未检测到对病灶大小的影响。
要点
- 西尼莫德3 mg/kg可显著诱导卒中后第7天淋巴细胞减少。
- 西尼莫德减少中枢神经系统T淋巴细胞积聚。
- 西尼莫德未减少梗死病灶体积,未提供神经保护临床前证据。
核心结论
- 在短暂大脑中动脉闭塞中年小鼠模型中,西尼莫德3 mg/kg未减少病灶体积,不提供S1PR1/5调节剂作为卒中神经保护剂的临床前证据。
研究设计与样本
- 研究在中年野生型小鼠中诱导短暂大脑中动脉闭塞,给予西尼莫德(3 mg/kg;腹腔注射)或溶媒治疗6天。
- 卒中结局通过磁共振成像(脾体积:卒中前、第3天和第7天;梗死体积:第1、3、7天)和行为学测试(卒中前、第2天和第6天)评估。
- 外周血免疫细胞及同侧和对侧脑浸润细胞通过VETScan和流式细胞术分析。
主要发现
- 西尼莫德显著诱导短暂大脑中动脉闭塞后第7天淋巴细胞减少。
- 西尼莫德减少中枢神经系统T淋巴细胞积聚。
- 未检测到西尼莫德对病灶大小的影响。
临床怎么用
- 该临床前结果不支持将S1PR1/5调节剂用于卒中神经保护治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The contribution of neuroinflammation and, in particular, the infiltration of the brain by lymphocytes is increasingly recognized as a substantial pathophysiological mechanism after stroke. The interaction of lymphocytes with endothelial cells and platelets, termed thromboinflammation, fosters microvascular dysfunction and secondary infarct growth. Siponimod is an S1PR (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment. We investigated the effect of treatment with siponimod on stroke outcome in a mouse model of cerebral ischemia. Methods- Transient middle cerebral artery occlusion was induced in middle-aged wild-type mice. Animals were either treated with siponimod (3 mg/kg; intraperitoneal) or vehicle for 6 days. Stroke outcome was assessed by magnetic resonance imaging (spleen volume: prestroke, day 3, and day 7; infarct volume: days 1, 3, and 7) and behavioral tests (prestroke, day 2, and day 6). Immune cells of the peripheral blood and brain-infiltrating cells ipsilateral and contralateral were analyzed by VETScan and by flow cytometry. Results- Siponimod significantly induced lymphopenia on day 7 after transient middle cerebral artery occlusion and reduced T-lymphocyte accumulation in the central nervous system. No effect was detected for lesion size. Conclusions- For siponimod administered at 3 mg/kg in transient middle cerebral artery occlusion mouse model, our findings do not provide preclinical evidence for the use of S1PR1/5 modulators as neuroprotectant in stroke therapy.
引用
- Vogelgesang A, Domanska G, Ruhnau J, et al. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke. Stroke. 2019. PMID: 31009359. doi:10.1161/STROKEAHA.118.023667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。